>
Biotest AG logo

BIO3 - Biotest AG Share Price

€30 -0.1  -0.3%

Last Trade - 09/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.03bn
Enterprise Value £1.36bn
Revenue £420.2m
Position in Universe 387th / 1045
Bullish
Bearish
Unlock BIO3 Revenue
Momentum
Relative Strength (%)
1m -2.21%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -4.15%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
534.6 408 378.1 400.3 419.1 484.2 508 549 -2.0%
+307.1 -93.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BiotestAG revenues increased 16% to EUR484.2M. Net loss applicableto common stockholders increased from EUR4.8M to EUR32.2M.Revenues reflect Therapy segment increase of 16% toEUR430.5M, Plasma & Services segment increase of 18% toEUR46.7M, Eastern and Southern Europe segment increase of37% to EUR116.5M, Middle East and Africa segment increaseof 40% to EUR109M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIO3 Revenue Unlock BIO3 Revenue

Net Income

BIO3 Net Income Unlock BIO3 Revenue

Normalised EPS

BIO3 Normalised EPS Unlock BIO3 Revenue

PE Ratio Range

BIO3 PE Ratio Range Unlock BIO3 Revenue

Dividend Yield Range

BIO3 Dividend Yield Range Unlock BIO3 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BIO3 EPS Forecasts Unlock BIO3 Revenue
Profile Summary

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since October 14, 1987
No. of Shareholders: n/a
No. of Employees: 1,928
Sector Healthcare
Industry Pharmaceuticals
Index Xetra Classic All Share , Xetra Prime All Share ,
Exchange XETRA (Dual Listing)
Shares in Issue 39,571,452
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIO3 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIO3
Upcoming Events for BIO3
Friday 7th May, 2021 Estimate
Biotest AG Annual Shareholders Meeting
Tuesday 11th May, 2021
Biotest AG Annual Shareholders Meeting
Wednesday 12th May, 2021
Dividend For BIOG_p.DE - 0.0400 EUR
Frequently Asked Questions for Biotest AG
What is the Biotest AG share price?

As of 09/04/21, shares in Biotest AG are trading at €30, giving the company a market capitalisation of £1.03bn. This share price information is delayed by 15 minutes.

How has the Biotest AG share price performed this year?

Shares in Biotest AG are currently trading at €30 and the price has moved by 37.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotest AG price has moved by 7.16% over the past year.

What are the analyst and broker recommendations for Biotest AG?

Of the analysts with advisory recommendations for Biotest AG, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biotest AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biotest AG next release its financial results?

Biotest AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Biotest AG dividend yield?

Biotest AG does not currently pay a dividend.

Does Biotest AG pay a dividend?

Biotest AG does not currently pay a dividend.

When does Biotest AG next pay dividends?

Biotest AG does not currently pay a dividend.

How do I buy Biotest AG shares?

To buy shares in Biotest AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biotest AG?

Shares in Biotest AG are currently trading at €30, giving the company a market capitalisation of £1.03bn.

Where are Biotest AG shares listed? Where are Biotest AG shares listed?

Here are the trading details for Biotest AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: BIO3
What kind of share is Biotest AG?

Based on an overall assessment of its quality, value and momentum, Biotest AG is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biotest AG share price forecast 2021?

We were not able to load any forecast data for Biotest AG.

How can I tell whether the Biotest AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotest AG. Over the past six months, the relative strength of its shares against the market has been -8.38%. At the current price of €30, shares in Biotest AG are trading at 14.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biotest AG PE Ratio?

We were not able to find PE ratio data for Biotest AG.

Who are the key directors of Biotest AG?

Biotest AG's management team is headed by:

Cathrin Schleussner - SUB
Kerstin Birkhahn - SUB
Michael Ramroth - CMG
Georg Floss - COO
Juergen Heilmann - SUB
Christina Erb - DHR
Rolf Hoffmann - CSU
Christine Kreidl - SUB
Katrin Bernoester - OTH
Enrico D'Aiuto - DSL
Stephan Fleck - CTR
Oliver Hein - CCO
Martin Moeller - FID
Tan Yang - VSU
Simone Fischer - SUB
Who are the major shareholders of Biotest AG?

Here are the top five shareholders of Biotest AG based on the size of their shareholding:

Ersel Asset Management SGR S.p.A. Investment Advisor/Hedge Fund
Percentage owned: 1.96% (388k shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 1.24% (246k shares)
FPS Vermögensverwaltung GmbH Investment Advisor
Percentage owned: 1.13% (223k shares)
Leadersel - Event Driven B Mutual Fund
Percentage owned: 1.07% (212k shares)
Hedgersel Hedge Fund Portfolio
Percentage owned: 0.89% (175k shares)
Similar to BIO3
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.